
In a recent episode of our “Molecular Imaging in Focus” series, Martin Pomper, MD, PhD, discussed the origin of PSMA PET, shared his perspective on non-PSMA targets in prostate cancer and offered his thoughts on the potential promise of emerging theranostics.




























